March 29, 2022
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022 Enrolled first patient in the…
Pharmaceuticals, Biotechnology and Life Sciences
Author: GlobeNewswire
March 29, 2022
Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors
-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication…
March 29, 2022
Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
– Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –REHOVOT, Israel and WILMINGTON, Del., March 28, 2022…
March 29, 2022
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing…
March 27, 2022
Sanofi: Information concerning the total number of voting rights and shares – February 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code…
March 27, 2022
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for…
March 27, 2022
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…
March 27, 2022
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly…
March 27, 2022
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
PHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a…
March 26, 2022
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on…